Alprolix Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The alprolix market size has grown strongly in recent years. It will grow from $1.32 million in 2025 to $1.45 million in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to high unmet need in hemophilia b management, limitations of plasma derived therapies, proven efficacy of recombinant factor ix, increasing diagnosis of inherited bleeding disorders, early adoption of prophylactic treatment protocols.

The alprolix market size is expected to see strong growth in the next few years. It will grow to $2.09 million in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising hemophilia b patient population, increasing demand for long acting clotting factors, improved access to specialty hemophilia care, expansion of home based infusion programs, continued innovation in factor fusion technologies. Major trends in the forecast period include growing adoption of extended half life factor ix therapies, increasing shift toward prophylactic hemophilia management, rising preference for reduced infusion frequency treatments, expansion of recombinant coagulation factor usage, improved patient adherence through long acting therapies.

The rising prevalence of hemophilia B is expected to drive the growth of the Alprolix market in the coming years. Hemophilia B, also known as Christmas disease, is a rare inherited bleeding disorder resulting from a deficiency or absence of clotting factor IX. The growing prevalence of hemophilia B is largely attributed to improved diagnostic methods, increased awareness and reporting, advancements in healthcare systems that enable earlier detection, and longer life expectancy among patients due to improved treatment options. Alprolix, a long-acting recombinant clotting factor IX, supports the management of hemophilia B by reducing bleeding episodes and decreasing the frequency of infusions through its extended half-life, thereby enhancing patients’ quality of life. For instance, in October 2025, according to a report published by the World Federation of Hemophilia (WFH), as of 2024 there were 271,918 identified patients with hemophilia worldwide, including 224,353 individuals with hemophilia A and 45,600 with hemophilia B. Therefore, the increasing prevalence of hemophilia B is driving the Alprolix market.

The Alprolix market has experienced notable advancements in recent years, supported by a growing emphasis on innovative therapies to address unmet needs in hemophilia B treatment. Factor IX gene therapies work by delivering a functional copy of the FIX gene using adeno-associated virus (AAV) vectors, enabling long-term production of clotting factor IX, reducing bleeding episodes, and potentially providing a one-time treatment option for hemophilia B. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical manufacturing company, received U.S. FDA approval for Beqvez™ (fidanacogene elaparvovec), a gene therapy developed to treat hemophilia B. This approval represents a major milestone in hemophilia care, offering the possibility of a single-treatment solution that may significantly reduce or eliminate the need for regular clotting factor infusions. The therapy delivers a functional copy of the recombinant factor IX gene, resulting in sustained factor IX levels and improved bleeding control, supported by clinical trial data demonstrating durable efficacy and a favorable safety profile in patients with severe or moderately severe hemophilia B.

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired Emergent BioSolutions for an undisclosed amount. Through this acquisition, Bora Pharmaceuticals aims to strengthen its presence in the biotechnology and pharmaceutical sectors by expanding its contract development and manufacturing organization (CDMO) capabilities. Emergent BioSolutions Inc. is a US-based company that provides recombinant coagulation factor IX-based therapies.

Major companies operating in the alprolix market are Sanofi.

North America was the largest region in the alprolix market in 2025. The regions covered in the alprolix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alprolix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately impacted the alprolix market by increasing costs associated with imported recombinant protein manufacturing inputs and specialized cold chain logistics. These effects are most visible in hospital and specialty clinic distribution channels across north america and europe. Higher tariffs have placed pressure on treatment pricing and reimbursement negotiations for hemophilia therapies. At the same time, tariffs are encouraging regional biologics manufacturing and local supply chain development. This supports long term availability of advanced coagulation therapies.

The alprolix market research report is one of a series of new reports that provides alprolix market statistics, including alprolix industry global market size, regional shares, competitors with a alprolix market share, detailed alprolix market segments, market trends and opportunities, and any further data you may need to thrive in the alprolix industry. This alprolix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alprolix is a recombinant coagulation factor IX Fc fusion protein used to treat and prevent bleeding episodes in individuals with hemophilia B. It works by replacing the missing factor IX to support normal blood clotting and features an extended half-life, which helps reduce the frequency of infusions needed for effective disease management.

The main products in the Alprolix market include recombinant coagulation factor IX and plasma-derived coagulation factor IX. Recombinant coagulation factor IX is a bioengineered protein designed to replace deficient or defective factor IX in patients with hemophilia B, enabling proper clot formation and reducing excessive bleeding. The available formulations include injectable solutions and powders for reconstitution. These products are used in applications such as hemophilia B treatment, prophylaxis, and surgical management and are distributed through hospitals, specialty clinics, and online pharmacies.

The alprolix market consists of sales of alprolix 250IU and alprolix 500 IU. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.